… respiratory rehabilitation on patients with interstitial lung disease (ILD) [21,22,23]. We excluded
patients who met the following exclusion criteria: (1) patients in an unstable condition; (2) …

… patients. Though MASLD occurs frequently, there is still no approved pharmacological treatment,
and the mainstay of therapy … implicates muscle mass and sarcopenia in disease-related …

… to identify probable sarcopenic patients, including deficiencies in … ), two tools that can rapidly
identify sarcopenic patients [93]. … Adiponectin performs anti-inflammatory, anti-fibrotic, and …

… medications became the standard of care for the treatment of IPF. As such, it … anti-fibrotic
therapy affects disease progression and whether anti-fibrotic treatment is as effective in patients …

… has antifibrotic effects on in vitro human fibroblasts [35], indicating the need for future studies
to explore the links between hormones, limb muscles, and disease progression in patients …

… Background NAFLD and sarcopenia are common diseases … is to explore associations
between sarcopenia, NAFLD and … Sarcopenia was defined as a ratio of ALM/BMI below 0.789 …

… (SGLT2i) empagliflozin demonstrates anti-fibrotic capabilities in various organs. … in sarcopenia,
our research may offer potential directions for drug therapy in the treatment of sarcopenia. …

… an anti-fibrotic agent in early diffuse cutaneous systemic sclerosis (dcSSc). Methods: Patients
already on anti-fibrotic therapy for … of the prevalence of sarcopenia in patients with SSc with …

… treatment. [ 3, 8 ] Therefore, we postulated that the combination of BCAAs and another …
with anti-sarcopenic effects would be more beneficial for treating sarcopenia in patients with …

… therapeutic options for IPF using a systematic computational approach for drug repositioning.
We also validated the antifibrotic effect … to determine whether sarcopenia could predict ILD …